|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-6-21
|
|
pubmed:abstractText |
Metformin is an effective treatment for type 2 diabetes mellitus. The pharmacokinetic characteristics of the conventional immediate-release (IR) formulation of metformin (Glucophage), however, necessitate two- or three-times-daily dosing. Development of a novel extended-release (XR) formulation of metformin (Glucophage XR) using GelShield Diffusion System technology provides a once-daily dosing option. The objective of this study was to assess the steady-state pharmacokinetics of metformin XR tablets.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0312-5963
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
721-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15966755-Administration, Oral,
pubmed-meshheading:15966755-Adult,
pubmed-meshheading:15966755-Area Under Curve,
pubmed-meshheading:15966755-Biological Availability,
pubmed-meshheading:15966755-Delayed-Action Preparations,
pubmed-meshheading:15966755-Dose-Response Relationship, Drug,
pubmed-meshheading:15966755-Drug Administration Schedule,
pubmed-meshheading:15966755-Female,
pubmed-meshheading:15966755-Gastrointestinal Diseases,
pubmed-meshheading:15966755-Half-Life,
pubmed-meshheading:15966755-Humans,
pubmed-meshheading:15966755-Hypoglycemic Agents,
pubmed-meshheading:15966755-Male,
pubmed-meshheading:15966755-Metformin,
pubmed-meshheading:15966755-Tablets,
pubmed-meshheading:15966755-Time Factors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Steady-state pharmacokinetics of a novel extended-release metformin formulation.
|
|
pubmed:affiliation |
Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Moreton, UK. peter.timmins@bms.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
